These findings suggest that switching to tirzepatide might be a better option than increasing dulaglutide for patients who ...

AWARD-11 showed 3.0 mg and 4.5 mg doses led to additional blood sugar control; as a secondary endpoint, both doses also led to weight loss INDIANAPOLIS, Sept. 3, 2020 /PRNewswire/ -- The U.S. Food and ...

Please provide your email address to receive an email when new articles are posted on . Dulaglutide, semaglutide and tirzepatide had similar GI safety profiles. An increased risk for GI adverse events ...

Risks for kidney failure and major cardiovascular events between three GLP-1 receptor agonists were similar among veterans with diabetes. Mortality risk and certain adverse events differed between the ...